SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_14: Pharmacokinetics of Co-encapsulated Truvada® with Ingestible Sensor to Assess Adherence- Nathan HananView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017DDI’s in Aging HCV infected Patients- Elise Smolders, MScView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017Long Acting Antivirals: Advanced drug delivery- Mark Milad, PharmDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017DDI’s in Aging HIV infected Patients- Alice Pau, PharmDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_12: Examining the Basis of Drug-Drug Interaction Labeling Recommendations for Antiviral Approvals from 1998 to 2015- Tyler Shugg, PharmD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_13: CYP3A induction data can predict other P450 and drug transporter DDI liability: An example of carbamazepine and rifabutin with sofosbuvir and P-gp- Brian Kirby, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017FDA perspective- Kellie Reynolds, PharmDView Slideset
JFJordan FeldMD, MPHSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017HBV therapy & Approaches to Cure- Jordan Feld, MD, MPHView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_11: HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.- Sandrine LefeuvreView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_10: Pharmacokinetics of Dolutegravir and Rilpivirine after Switching to the Two-Drug Regimen from an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1/2 Pooled PK Analysis- Kimberly Adkison, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_7: A Comparison of the Pharmacokinetics of Dolutegravir during Pregnancy and Postpartum- Dr Pauline BollenView Slideset
MBMarta BoffitoMD, PhD, FRCP, MBASlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_8: Relationship between dolutegravir plasma exposure, quality of sleep and its functional outcome in patients living with HIV over the age of 60 years.- Marta Boffito, MD, PhD, FRCPView Slideset
